188 related articles for article (PubMed ID: 34108028)
1. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
2. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
4. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
6. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
8. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
[TBL] [Abstract][Full Text] [Related]
9. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
10. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening.
Hayashi Y; Inaba T; Hanada R; Yamamoto K
J Pediatr; 1988 Apr; 112(4):567-71. PubMed ID: 3351679
[TBL] [Abstract][Full Text] [Related]
11. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
Wang H; Wang X; Xu L
Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
[TBL] [Abstract][Full Text] [Related]
14. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.
Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T
J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005
[TBL] [Abstract][Full Text] [Related]
16. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
17. Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases.
Hachitanda Y; Hata J
Hum Pathol; 1996 Nov; 27(11):1135-8. PubMed ID: 8912820
[TBL] [Abstract][Full Text] [Related]
18. Inverse expression of MYCN and mdr-1 in human neuroblastoma.
Nakagawara A; Kadomatsu K; Sato S; Kohno K; Takano H; Kuwano M
Prog Clin Biol Res; 1991; 366():11-9. PubMed ID: 2068131
[No Abstract] [Full Text] [Related]
19. Competitive polymerase chain reaction for the determination of N-myc amplification in neuroblastoma: report of clinical cases.
Hasan Z; Inoue A; Ikeda H; Kamii Y; Obana K; Yokomori K; Tsuchida Y; Hemmi H; Shimatake H
Eur J Pediatr Surg; 1999 Jun; 9(3):138-41. PubMed ID: 10427487
[TBL] [Abstract][Full Text] [Related]
20. Problems of mass screening for neuroblastoma: analysis of false-negative cases.
Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y
J Pediatr Surg; 1990 Apr; 25(4):398-401. PubMed ID: 2329455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]